<DOC>
	<DOCNO>NCT02384395</DOCNO>
	<brief_summary>This multicenter , single arm , 96-week open-label study safety virologic efficacy fix dose combination Dolutegravir/Lamivudine/Abacavir ( DTG/3TC/ABC FDC ) initiate acute HIV infection ( AHI ) .</brief_summary>
	<brief_title>Safety Efficacy Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection</brief_title>
	<detailed_description>The study conduct University North Carolina Chapel Hill , NC Duke University Durham , NC . All forty ( 40 ) participant enrol 96 week receive DTG/3TC/ABC FDC . We propose evaluate efficacy time viral suppression DTG/3TC/ABC FDC initial therapy AHI ( acute HIV infection ) , well feasibility prompt administration use rapid HLA-B57 ( human leukocyte antigen ) screen antibody assay . In addition validate restriction RCI ( rest cell infection ) ART ( antiretroviral therapy ) include DTG-based regimen initiate AHI , seek correlation low RCI , residual GALT ( gastrointestinal associate lymphoid tissue ) HIV expression , measure immune activation . We hypothesize rapid reduction plasma viremia regimen limit area pre-ART viral load curve , thus reduce latent reservoir size measure viral outgrowth assay one two year follow ART start , compare latent reservoir size acutely infected individual start regimen without integrase inhibitor base regimen . In addition , examine longitudinal impact propose integrase-based regimen initiate acute period immune activation week 96 . If residual viral expression persistent immune dysfunction relate burden latent viral reservoir ( presumably periodic activation ) abnormality ameliorate early ART rapid viral suppression . Finally , evaluate dolutegravir level plasma GALT whether rapid viral suppression propose dolutegravir-based ART regimen impact HIV RNA level GALT .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Inclusion Criteria 1 . Documentation Acute HIV infection within 30 day study entry . 2 . Men woman age ≥18 year . 3 . ART naive , defined ≤14 day antiretroviral treatment time prior entry . The exception : Preexposure prophylaxis ( PrEP ) document HIV1 negative least 1 month prior AHI diagnosis PrEP , Postexposure prophylaxis ( PEP ) provide participant document HIV1 negative least 36 month follow completion PEP treatment . 4 . Lab value obtain within 30 day prior study entry : Absolute neutrophil count &gt; 500/mm3 Hemoglobin &gt; 8.5 g/dL men &gt; 8.0 g/dL woman Platelet count &gt; 50,000/mm3 Lipase ≤ 3 X upper limit normal ( ULN ) , single repeat test allow determine eligibility Calculated creatinine clearance ( CockcroftGault formula ) ≥ 50mL/min : CrCl = ( 140age ) x body weight ( kg ) ( x 0.85 female ) Serum creatinine [ mg/dL ] x ( 72 ) 5 . Testing HBsAg pending . Note : Participants test positive HBsAg terminate study prior start study treatment . 6 . Testing HLAB57 and/or HLAB*5701 pending . Note : Participants test positive HLAB*5701 terminate study prior start study treatment . 7 . A female eligible enter participate study : Is nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhea ≥ 45 year age ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy ; , Is childbearing potential , negative pregnancy test screening enrollment , agree use one method contraception list . Complete abstinence intercourse 2 week prior administration study medication , throughout study , least 2 week discontinuation study medication ; Double barrier method ( male condom/spermicide , male condom/diaphragm , diaphragm/spermicide ) ; Approved hormonal contraception use alone consider sufficient form contraception study see Appendix 1 listing example approve hormonal contraception ; Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ; see Appendix 2 list IUDs meeting criterion ; Male partner sterilization confirm prior female participant 's entry study , male sole partner patient ; Any method publish data show expected failure rate &lt; 1 % per year . Any contraception method must use consistently , accordance approve product label least 2 week discontinuation study medication . 8 . Ability willingness participant give write informed consent . Exclusion Criteria 1 . ALT ≥ 5 time Upper Limit Normal ( ≥5xULN ) 2 . AST ≥ 3x ULN 3 . Bilirubin ≥1.5x ULN ( &gt; 35 % direct bilirubin ) 4 . Women breastfeed . 5 . Women positive pregnancy test enrollment prior study drug administration . 6 . History presence allergy study drug component . 7 . Requires anticipated require prohibit concomitant therapy : barbiturate , dofetilide , modafinil , oxcarbazepine , pioglitazone , pimozide , rifampin , rifapentine , phenytoin , phenobarbital , carbamazepine , St. John 's wort . Dofetilide prohibit , DTG may inhibit renal tubular secretion result increase dofetilide concentration potential toxicity . 8 . Unable discontinue current medication exclude study treatment . 9 . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , radiation therapy , HIV vaccine , systemic cytotoxic chemotherapy , investigational therapy within 30 day prior study entry . Prednisone daily dose 10 mg less ( physiologic replacement dose ) permit . 10 . Treatment radiation therapy cytotoxic chemotherapeutics agent within 28 day prior screen anticipate need agent study . 11 . Administration HIV1 immunotherapeutic vaccine within 90 day prior screen . 12 . Prior treatment experimental drug indication ( within 30 day initiate study treatment ) . 13 . Difficulty swallow capsules/tablets . 14 . Inability communicate effectively study personnel . 15 . Incarceration ; prisoner recruitment participation permit . 16 . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement confound analysis study endpoint . 17 . Any condition ( include limit alcohol drug use ) active clinically significant disease finding screen medical history physical examination , , opinion Investigator would interfere patient safety compliance . 18 . Serious illness require systemic treatment and/or hospitalization patient either complete therapy clinically stable therapy , opinion site investigator , least 7 day prior study entry . NOTE : Oral candidiasis , vaginal candidiasis , mucocutaneous herpes simplex , minor illness ( judge site investigator ) restriction . 19 . A life expectancy less twelve month . 20 . Acute viral hepatitis , include , limited , hepatitis A , B , C. 21 . History myocardial infarction diagnosis coronary artery disease . 22 . History ongoing clinically relevant pancreatitis within previous 6 month . 23 . Chronic hepatitis C infection anticipate need treatment study period ( week 96 ) . 24 . Chronic hepatitis B infection ( see inclusion criterion 5 ) . 25 . Evidence moderate severe hepatic impairment ( define presence cirrhosis , ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ChildPugh class B great hepatic impairment ) . 26 . Evidence biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 27 . Any verified grade 4 laboratory abnormality exception ALT define exclusion criterion 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Dolutegravir</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>acute HIV infection</keyword>
	<keyword>human leukocyte antigen</keyword>
	<keyword>latent HIV reservoir</keyword>
	<keyword>integrase-based regimen</keyword>
	<keyword>viremia</keyword>
	<keyword>antiretroviral therapy</keyword>
	<keyword>fix dose combination</keyword>
</DOC>